Abstract 293P
Background
OXN PR, a fixed dose combination of opioid and peripherally-acting mu-opioid antagonist, offers analgesia while reducing opioid-induced constipation (OIC). Few have studied OXN vs other strong opioids for impact on bowel function, safety and QoL in patients with CP.
Methods
Systematic review of literature from PubMed and EMBASE that evaluated analgesia, bowel function, adverse events (AE) and QoL after OXN PR or oral oxycodone (OXY)/morphine/tapentadol PR, or transdermal fentanyl, in adults with moderate-severe CP. Data for outcomes were extracted from publications or clinical study reports.
Results
4 RCTs (OXN vs OXY) were found; no RCT compared OXN vs other strong opioids. Analgesia and safety were comparable with OXN or OXY, except for nausea that was less frequent with OXN (Odds ratio: 0.51 [0.26, 0.97]). Most AEs related to OXN and OXY were mild-moderate severity; most common were gastrointestinal disorders. Improved bowel function (BFI, PAC-SYM) was observed with OXN vs OXY (Table). QoL was comparable with OXN or OXY (Global health status, mean difference: 0.5 [-4.7, 5.7]). Table: 293P
Descriptive findings for bowel function
RCTs | Findings | OXN vs OXY | |
BFI | |||
Scores over 4 weeks | 2 | Δ mean (% improvement)† | RCT 1: -25.1 (39.2%) vs -13.6 (21.7%) RCT 2: -36.0 (50.7%) vs -25.0 (36.8%) |
Score comparison at week 4 | 1 | LS mean difference (SE) | -11.1 (4.00) |
95% CI‡ | [-19.0, -3.2] | ||
P value‡ | 0.006 | ||
PAC-SYM | |||
Total score | 1 | Δ mean (% improvement)† | -7.0 (40.3%) vs -2.7 (15.1%) |
P-value§ | 0.0014 | ||
Symptom frequency | 1 | Δ mean (% improvement)† | -1.1 (41.9%) vs -0.3 (12.9%) |
P value§ | <0.001 |
†baseline to week 4 ‡adjusted for baseline using ANCOVA model. §between-group difference; derived from summary statistics LS, least squared.
Conclusions
Systematic review found only direct comparisons of OXN vs OXY in RCTs of CP. OXN provided similar analgesia and safety to OXY for CP with less nausea and improved bowel function, in terms of constipation symptoms. OXN is a valuable analgesic option in patients with OIC or nausea from cancer itself or anticancer treatment. Although limited, this meta-analysis confirms existing evidence on OXN’s efficacy and tolerability in patients with moderate-severe CP and highlights that few data on OXN in CP is available.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Wei Yi Kwok and Geraldine Toh from Tech Observer Asia Pacific Pte Ltd.
Legal entity responsible for the study
Mundipharma Singapore Holding Pte Ltd.
Funding
Mundipharma Singapore Holding Pte Ltd.
Disclosure
S.H. Ahmedzai: Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Mundipharma. L. Langenhoven: Advisory/Consultancy, Speaker Bureau/Expert testimony: Mundipharma. C. Minnaert, Y. Hadjiat: Full/Part-time employment: Mundipharma. All other authors have declared no conflicts of interest.
Resources from the same session
424P - Hippocampus sparing in volumetric modulated arc therapy (VMAT) for brain tumour radiotherapy treatment
Presenter: Eva Yi Wah Cheung
Session: e-Poster Display Session
425P - The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents
Presenter: Chun Loo Gan
Session: e-Poster Display Session
426P - A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Presenter: Marcia S. Brose
Session: e-Poster Display Session
427P - On the clinical implications of systemic and local immune responses in human angiosarcoma
Presenter: Jason Yongsheng Chan
Session: e-Poster Display Session
428P - Prognostic value of clinico-pathological characteristics and peripheral monocyte counts in localised extra-meningeal solitary fibrous tumours treated with surgical resection
Presenter: Ryan Lim
Session: e-Poster Display Session
429P - Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India
Presenter: Anshul Agarwal
Session: e-Poster Display Session
430P - Teenagers and young adult cancers in rural central India: Access to age-appropriate care
Presenter: Runu Sharma
Session: e-Poster Display Session
431P - Quantitative study of two critical lncRNAs in patients with glioma tumours
Presenter: Kamal Mohammadian
Session: e-Poster Display Session
432P - Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Presenter: Mustafa Gürbüz
Session: e-Poster Display Session
433P - Association between aspirin and cancer risk: A Mendelian randomization analysis
Presenter: Yu Jiang
Session: e-Poster Display Session